TSLA Stock Today: February 10 – NASA Crew-12 Coverage Puts SpaceX in Focus
TSLA stock today: How NASA’s SpaceX Crew-12 live coverage could sway Tesla sentiment for Hong Kong investors. Key HKT timings, levels, technicals, ratings, and risks.
Timely insights on global market trends, industry developments, and investment shifts.
TSLA stock today: How NASA’s SpaceX Crew-12 live coverage could sway Tesla sentiment for Hong Kong investors. Key HKT timings, levels, technicals, ratings, and risks.
Gen Z handwriting is back, boosting smart pen demand in Switzerland. We analyze digital pen market drivers, Nuwa Pen buzz, and investor signals Swiss buyers should track in 2026.
HeroGo’s £12 boxes put surplus food delivery in focus in London. We assess pricing, demand, and risks as cheaper, sustainable grocery options pressure meal kits and couriers.
Mortgage rates today hover near 6.15–6.20% for 30-year loans as refi hits 6.61%. We explain what this means for Australians comparing loans, refis, and lenders.
Premium Brands stock is in focus in Canada after the US$688M Stampede acquisition. With margins improving and a CA$10B 2027 revenue target, we assess upside toward CA$127 and key catalysts for a rerat
Bitcoin rebounds toward US$70K while derivatives stay cautious. A Canada-focused guide to cryptocurrency trading today: funding rates, options skew, key levels, and risk tactics for BTC.
USD/JPY slipped to 155.8 as Japan’s officials stressed “dialogue” with markets, lifting yen intervention risk. We explain why 160 matters, the 155–161 range, and what JP investors should watch amid FX
Goldman Sachs Anthropic tie-up targets faster KYC and trade accounting. See GS stock news, technicals, earnings watch, and what this AI move means for Indian investors and IT vendors.
ASX futures point higher as a Wall Street rally and a Nikkei record high lift risk appetite. What to watch for ASX 200 today, key data risks, sectors, and the AUD.
Novo Nordisk stock fell 27% this week after 2026 revenue guidance flagged a 5–13% decline. Shares rebounded Friday as FDA backed legal action on semaglutide copycats. Swiss investor takeaways.